BiotechTube

SHR-1916

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Unspecified Adult Solid Tumor, Protocol Specific

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Trial Timeline

Apr 8, 2021 → Nov 1, 2022

NCT ID
NCT04842630

About SHR-1916

SHR-1916 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Unspecified Adult Solid Tumor, Protocol Specific. The current trial status is terminated. This product is registered under clinical trial identifier NCT04842630. Target conditions include Unspecified Adult Solid Tumor, Protocol Specific.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04842630Phase 1Terminated

Competing Products

20 competing products in Unspecified Adult Solid Tumor, Protocol Specific

See all competitors
ProductCompanyStageHype Score
DJ-927 + capecitabineDaiichi SankyoPhase 1
33
E7389 + E7389 + E7389EisaiPhase 1
33
bevacizumab + enzastaurin hydrochlorideEli LillyPhase 1
33
PembrolizumabMerckPhase 2
52
PI3K inhibitor BKM120 + docetaxelNovartisPhase 1
33
bevacizumab + cyclophosphamide + imatinibNovartisPhase 1
33
capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)NovartisPhase 1
33
warfarinNovartisPhase 1
33
RLY-1971RochePhase 1
33
Domvanalimab + ZimberelimabGilead SciencesPhase 1
32
BEZ235 + MEK162PfizerPhase 1
32
Utomilumab + ISA101bPfizerPhase 2
51
IrinotecanPfizerPhase 1
32
Ixabepilone + SunitinibPfizerPhase 1
32
ixabepilone + lapatinib ditosylateBristol Myers SquibbPhase 1
32
carboplatin + irinotecan hydrochlorideBristol Myers SquibbPhase 1
32
intoplicineSanofiPhase 1
32
apomineSanofiPhase 1
32
apomineSanofiPhase 1
32
SorafenibBayerPhase 2
49

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85